Nektar Therapeutics YTD Return
Start date: 12/31/2018
End date: 06/17/2019
Start price/share: $32.87
End price/share: $33.70
Dividends collected/share: $0.00
NKTR YTD return: 2.53%
Annualized Gain: 5.52%
Starting investment: $10,000.00
Ending investment: $10,253.00
Years: 0.46


Nektar Therapeutics YTD return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare NKTR YTD return (see YTD Return Meaning) versus benchmarks:

YTD Return S&P
YTD Return Dow
YTD Return Nasdaq 100
YTD Return Russell 2000
YTD Return Gold
YTD Return 10 Year Treasury
YTD Return By Sector
YTD Return on $10,000.00
Without Dividends Reinvested Into NKTR

Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s proprietary drugs and drug candidates that have either received regulatory approval or are being developed by Co. or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD™, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology. The Nektar Therapeutics YTD return is shown above.

The YTD Return on the Nektar Therapeutics YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely useful in the context of our country's tax system which taxes gains and income on a calendar year basis.

Thus, researching Year-To-Date Returns is good practice for investors — whether Nektar Therapeutics YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the NKTR YTD return calculation (with any dividends reinvested as applicable), and to provide a coverage universe of many stocks and ETFs to be able to compare YTD returns.
Quotes delayed 20 minutes
Get Free SEC filing alerts for NKTR:
NKTR SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in YTD Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Nektar Therapeutics (NKTR) is categorized under the Healthcare sector; to help you further research YTD return performance across stocks, below are some other companies in the same sector:

NLNK YTD Return
NOVN YTD Return
NSTG YTD Return
NTLA YTD Return
NTRA YTD Return
NTRP YTD Return
NURO YTD Return
NUVA YTD Return
NVAX YTD Return
NVIV YTD Return
More Healthcare companies »

 

Nektar Therapeutics YTD Return | www.YTDReturn.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in YTDReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.